Medical Oncology

Breast Cancer   

Questions discussed in this category



While the KATHERINE trial for HER2+ used path staging, CREATE-X for TNBC with capecitabine used the Japanese Breast Cancer Society response criteria. ...

NCCN gives category 2b recommendation for either ER+ or ER-, HER2+ tumors, from the Tolaney NEJM 2015 paper with trastuzumab/paclitaxel.  However...

Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?

< 4 lymph nodes involved, initial diagnosis was 11 years ago when she was treated with mastectomy and adjuvant tamoxifen for 5 years.  

Would you consider still immunotherapy even if aggressive disease vs single agent chemotherapy?

Would it affect your decision whether original primary tumor and treatment was hormone positive or negative?

Does the SYSUCC-001 trial presented at ASCO 2020 change your practice?

How would your treatment change given pCR rates are reportedly much lower in triple positive patients?

This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...

Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...

For patients with low risk, early stage, hormone receptor positive, HER2 negative breast cancer who initiated endocrine therapy in order to delay thei...

Patient previously received neoadjuvant carboplatin, anthracycline and taxane regimen and is BRCA negative.

Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?

How would this change if the patient had metastatic HR+,HER2- breast cancer and now has symptomatic pancytopenia secondary to BM involvement after TCH...

Would you consider genomic assays before neoadjuvant chemotherapy? How would you modify your treatment given the COVID-19 pandemic?

T1a - 2mm; N1 - 1 ipsilateral lymph node measured 6mm Oncotype says too small to test and NGS says too few cancer cells to determine status.

Due to the apparent thrombogenic risk of COVID-19, would you consider holding tamoxifen in patients who test positive?

Given the changing landscape of treatment, some patients may have already received capecitabine previously.  Would this impact your treatment rec...

Would the recommendation differ based on HR+ vs. TNBC vs HER2+ classification? Would you recommend against immediate breast reconstruction?

Personally, my practice is to guide patients directly to surgery or to do neoadjuvant chemotherapy rather than to do neoadjuvant endocrine therapy, bu...

For example, if you had a triple positive breast cancer found on breast biopsy and repeat ER/PR/HER2 testing at the time of surgical resection showed ...

When a physical exam is important and telehealth is not a good option, should we be proactive and reschedule or should we continue to see them as sche...

ie, not a classic NTRK3-ETV6 fusion.The patient has progressed through CDk4/6 inhibitors and intolerant of alpelisib, and does not want chemotherapy.&...

She has no other site of disease progression and has been on an aromatase inhibitor (progressed in the CNS while on a study with adjuvant abemaciclib)...

The APT trial reported excellent DFS, OS and RFI for tumors <=3cm but few were smaller T2s (2-3 cm) and few were >70 years old.

This patient is interested in conceiving and therefore would like to wait to start the tamoxifen.

For example, if a patient had testosterone pellets injected, perhaps making endocrine therapy less efficacious, would that sway you to use chemo?

Being that this is a favorable histology would you use Oncotype Dx to help decide on neoadjuvant chemotherapy? Would you recommend neoadjuvant endocri...

In the absence of side effects, would you be inclined to continue beyond 10 years as chemoprevention? Would you factor an intermediate/high oncotype R...

How would you manage symptoms? How would you adjust the adjuvant regimen (dose reduce, omit paclitaxel etc)? What strategies would you consider for pr...

Data presented at the 2017 SABCS (abstract GS1-01) of the EBCTCG meta-analysis stating a benefit of dose-dense chemotherapy applies to ER positive and...

Would you recommend it for a mammographically occult primary or if the patient had dense breasts?  What if a high risk patient decides not to hav...

Endocrine therapy is usually not indicated for DCIS s/p bilateral mastectomy, but would the fact that residual tissue (nipple-sparing) alter your deci...

Would you offer adjuvant chemotherapy to a post-menopausal woman with a BRCA2 mutation and a T2N0 ER positive breast cancer with an oncotype of 12?

It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.

She had disease progression on palbociclib and letrozole. She also has a PIK3CA mutation however did not tolerate alpelisib due to Grade 3 hyperglycem...

Knowing that benefit of contralateral mastectomy is lower in older women who has already manifested BRCA related cancer and 10-20 % mastectomy related...

Margins were negative and there was no evidence of LCIS or lobular component in the lumpectomy specimen. Role for possible mastectomy?    ...

Does the results of the tnAcity trial influence your decision in choosing a 1st line option?

Status post nasolacrimal stent with improvement.  Would you re-challenge or permanently discontinue docetaxel?

More generally, do absorption issues effect the efficacy of tamoxifen and/or aromatase inhibitors?

Prior localized HR+,HER2- breast cancer treated with adjuvant AC-T (5years ago) Recent ipsilateral axillary recurrence (HR-,HER2+) s/p neoadjuvant TC...

Would you consider an aggressive approach with RT and/or surgery to the bone lesion and treat the primary as locally advanced breast cancer?

Received neoadjuvant ddAC/T followed by adjuvant capecitabine for residual disease and found to have metastatic pulmonary nodules within months of sur...

How would you approach a post-menopausal woman who now wishes to start adjuvant endocrine therapy more than 3 years since surgery?  

Would you prefer first-line AI/CDK 4/6 inhibitor, or first-line AI followed by 2nd-line fulvestrant/CDK 4/6 inhibitor (either abemaciclib, once availa...

If yes, would you still recommend dual HER2 directed therapy? After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...

Given that DBA is associated with increased incidence of MDS, AML and other solid tumors, would this modify your treatment recommendations?

For early stage disease in a single breast, would you consider neoadjuvant chemotherapy or upfront surgical staging followed by adjuvant therapy? What...

Do you tailor treatment to a goal response?  Do you refer to data illustrating improved prognosis if the patient develops a CR or PR?

Provided the sternal lesion was low volume and treated with curative intent and patient has been on tamoxifen for < 5 years, would you switch to AI...

PIK3CA and ESR1 mutations on NGS without other targets and who has progressed on CDK 4/6 & AI and several single agent chemotherapies.  Aside...

Would you substitute the paclitaxel for an alternative agent or just abort chemotherapy? How might your plan change in ER+ or ER- patients?

Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?  

Tamoxifen prophylaxis has not been studied in women <35 years old, but it would be reasonable to assume they would benefit.

I have seen some advocate for this in the community, although a Cochrane metanalysis did not find an advantage to giving the taxane earlier.

In a patient with who had undergone neoadjuvant TCH-P, lumpectomy, and RT and is currently on AI, pertuzumab, and trastuzumab, how do you think about ...

Neratinib was studied following adjuvant trastuzumab. Do you extrapolate that data to give neratinib to patients who have received adjuvant T-DM1 inst...

The ABC trials (Blum, JCO, 2017) used six cycles of TC. Is it because of the superiority seen with TC x four cycles versus standard AC x four cycles (...

Often patients are referred to medical oncology for adjuvant therapy for early stage breast cancer after BCS and just before starting radiation.

The GeparSixto, CALGB 40603, and more recently Prospero support doing it; however, it is not currently endorsed by NCCN and the latter Prospero s...

She developed biopsy proven skin nodules while on paclitaxel. PDL-1 positive and BRCA negative. Would you consider atezolizumab with a different agent...

She is otherwise asymptomatic and no LFT abnormalities. Would you switch to chemotherapy or offer different endocrine therapy?

Do you follow invasive or DCIS guidelines? Would you consider re-excision in a patient with multifocal microinvasive carcinoma of the breast arising i...

Why do the NCCN guidelines suggest using neoadjuvant therapy only for patients with T2 or greater tumors?

 If so, would you treat as node + BC with  anthracycline and taxane regimen or   non-anthracycline regimen (i.e  docetaxel and cyc...

Patient defers chemotherapy. She is currently on anastrozole/Herceptin and perjeta with a response but it is suboptimal. I would like to add a CDK 4/6...

Data was presented at ASCO in 2017 that abemaciclib has brain activity in HR positive breast cancer.

Most guidelines recommended adjuvant chemotherapy if tumor size was >3cm at the time of TAILOR Rx and patients with tumors >5cm were not include...

The use of neoadjuvant CDK 4/6 inhibitors is not standard of care, but there are clinical trials looking at this question and patients who are chemoth...

AI+ CK4/6 inhibitor? Fulvestrant + CK4/6 inhibitor? AI + fulvestrant? AI + fulvestrant + CK4/6 inhibitor?

Would you proceed with modified radical mastectomy followed by systemic therapy, or would you consider neoadjuvant therapy? Would biomarker status mat...

Does the presence of N1 disease push you towards offering chemotherapy or would you continue endocrine therapy based on the PR?

The woman was on on a GnRH agonist + AI due to her premenopausal status at diagnosis and now wants to know if she continues to need the GnRH agonist.&...

I know that many advocate using vaginal estrogen in this situation.  Most of the studies of vaginal estrogen in this situation have been small an...

In obese patients, would it make sense to switch from a GnRH agonist to an antagonist based on the data from the recent JCO study of dagrelix vs. trip...

NCCN recommendations seem to mention these patients as not candidates for preoperative systemic therapy if the invasive carcinoma extension cannot be ...

What would be the optimal sequence of surgery, radiation, and chemotherapy for this patient? This patient has an excellent performance status and...

For example, a patient has had multiple dose reductions for neutropenia and required an admission for infection while on palbociclib. Would you switch...

Clinical T1c patients were included in the KATHERINE trial that often are treated with adjuvant paclitaxel and trastuzumab

Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?

Would you maintain dose density of chemotherapy and use peg-filgrastim prior to delivery of the baby? Would you defer taxane and anti-HER2 therapy unt...

If so, what would be the regimen that you would consider and what factors would sway you for or against chemotherapy for such patients?

The ABC trials show a DFS advantage of anthracycline-based regimens. Would age alone procure you from using it in a patient?

This patient is a young lady with stage IV ER/PR positive, Her2 negative with oligometastatic  breast cancer undergoing a planned bilateral oophe...

Can repeating Oncotype on a locoregional recurrence show a change in the biologic behavior of the cancer over time and guide treatment decisions?

The recurrence was 2 years after treatment with ddAC + T.  If you elect for systemic therapy after local therapy, what chemotherapy would you use...

Is there a subset of patients for which you consider one regimen over the other (i.e. AC-THP v.TCHP)? If using an anthracycline regimen, do you u...

One such patient progressed through trastuzumab/pertuzumab/letrozole and TDM1 alone.  How would you combine ER+ approaches (eg CDK 4/6 inhibitor ...

Do your recommendations differ if patients are pre or postmenopausal given the data?

For instance, in stage III, would you use chemotherapy in neoadjuvant or adjuvant setting?  What regimen would you use?

And how long? According to the ABCSG-16 Trial there was no difference in extending AI beyond 2 years after an initial 5 years.  

Does the answer vary based on whether it is neo/adjuvant or metastatic setting?

One example is the original breast cancer ER high 90%, PR mod to high 40%, Her2 negative.  A liver metastasis diagnosed 2 years later showed ER l...

For example first-line ribociclib/letrozole, and second-line palbociclib/fulvestrant?  Without data, would there be any expected benefit?

The patient was previously treated with TAC x 6 (cumulative Adriamycin dose of 300 mg/m2) for a triple negative breast cancer. She is now with node-po...

OS benefit was limited to patients with endocrine sensitivity, defined as either a documented clinical benefit (CR, PR, or SD for ≥24 weeks) f...

Does an age over 70 years, size, histology and hormone receptor status affect this decision? 

The patient only had disease involving the right breast and axillary, cervical, and supraclavicular lymph nodes. She had complete response to with ddA...

Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?

There is a gray area in clinical decision making where the practice seems to be different for borderline size tumors such as a 7 mm lesion with no oth...

If yes, what dosage and do you use it continuously or intermittently? Regarding provera, many patients with ER/PR (+) breast cancer worry about taking...

Not to decrease recurrence risk, but for chemoprevention of new ER-positive DCIS or invasive disease based on the Gail Model. If so, is there data to ...

Other than when there are obvious contraindications to anthracycline, such as cardiac dysfunction, when do you use a non-anthracycline containing regi...

The patient is a pre-menopausal woman with low-grade, stage I IDC who initially could only tolerate 10 mg of tamoxifen for her first year of trea...

Young woman with Her2 positive disease involving her right breast, regional lymph nodes, and liver had a CR on PET after therapy with THP and now plan...

The NEJM 2015 paper by Tolaney et al only included 1.5% of patients with micrometastases.

If a patient has ER/PR+ and Her2 positive disease in the primary tumor while axillary lymph node core biopsy is ER/PR+ Her-2 negative, do you man...

In a patient treated over 10 years ago with mastectomy and chemo now with recurrence in the ipislateral axilla, would you offer additional with chemot...

If a patient previously received taxane-based chemotherapy for ER/PR+ Her2 negative disease three years ago, is additional chemotherapy recommended at...

Specifically, this patient had a new left lacrimal gland metastatic lesion that developed four years from her initial diagnosis and is currently under...

Would you do this for ER+ patients? According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...

I have a patient who will be climbing to the base camp of Mount Everest. Does a climb to 15,000 feet increase her risk? Should she wear a compression ...

Would you give neoadjuvant chemotherapy in a patient with T1 N1 M0 ER/HER-2 positive cancer if they are candidates for upfront lumpectomy?

If there is no response to neoadjuvant AC -->T, would you offer additional adjuvant chemotherapy?

High enough risk to justify anthracycline+taxane chemotherapy followed by ovarian suppression + aromatase inhibition.

Many times we encounter patients who do not have a tissue sample readily available or in whom obtaining such a sample would be hard. On a more molecul...

The PERSEPHONE trial to be presented at ASCO suggests 6 months of Herceptin is non-inferior to 12 months in early Her2 postive disease.

With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data a...

What is the optimal regimen for a pre-menopausal female with progression of ER+,PR+ and Her2 neu negative breast cancer while on tamoxifen for six mon...

The patient initially had a great response to THP for four months, but now with quite a bit of lung, pleural, and nodal involvement.

Do you offer additional adjuvant chemotherapy, proceed to adjuvant endocrine therapy, or search for a suitable clinical trial?

Intramammary lymph node involvement has been shown to have a poorer prognosis (Hogan, Surg Onc, 2010). Would Oncotype be useful in these patients...

Knowing that the analysis now is more detailed than it was 10 years ago. What about non-Ashkenazi Jewish breast cancer patients with suspic...

While we await the results of TailorX, what has been the experience in your practice? If the decision for adjuvant chemotherapy is made, do you f...

Patient does not qualify for breast cancer screening by annual MRI per criteria (IBIS lifetime risk<20%, no known genetic predisposition,...

What do you do/say when a discussion of evidence-based information doesn't convince a patient that this is her best chance of cure? Some patients even...

Originally received anthracycline and taxane based regimen.  Would you use carbo/paclitaxel or capecitabine or a different approach?

Would you treat this as a locally advanced breast cancer and offer surgery, radiation, and systemic therapy? Does your management change depending on ...

Is there a difference among all the commercial genetic testing labs? Is there anything beyond CLIA- and CAP-certification that we should look for...

After mastectomy for the locally recurrent disease, would you consider "pseudo-adjuvant" chemotherapy for local recurrence per the CALOR trial? If so,...

Can you apply the ACOSOG Z0011 study to women who have HER2 positive disease?  

Recent NEJM study showed an increased breast cancer relative risk in longer durations of hormonal contraceptive use that could last up to 5 years. Pre...

An article (BRCA mutation and outcome in BC. Ellen Copson, et al. Lancet Oncol. 2018) showed G3, BRCA+ breast cancer had poorer prognos...

http://www.nejm.org/doi/full/10.1056/NEJMoa1612645?rss=searchAndBrowse&#article_abstract If so, how do you sequence it with adjuvant radiotherapy...

Pt has progressed on AI and Faslodex. Goal is radiation to axilla as a palliative intent and Capecitabine to control systemic disease. 

Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?

If so, when? Are there certain ERBB2 mutations that would predict response to trastuzumab and/or neratinib? 

Following the dosage guidelines based on absolute neutrophil count may cause the patient to end up receiving lower doses.

Would you consider using CKD inhibitors upfront in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Hercepti...

This is in regards to the risk of secondary cancers after radiation therapy or cytotoxic chemotherapy (such as anthracyclines) in an immunosuppre...

Would you try to treat the single met with radiation and then treat it as locally advanced breast cancer?

Would you treat with 1st line AI/CDK inhibitor if patient is only low or moderately ER positive? ( example between 1-30%)

Assuming the patient was initially treated with surgical resection and adjuvant chemotherapy followed by radiation and appropriate endocrine therapy.

What do you do with low grade (grade 1/3) tumors? In other words, does high grade pathology over rules?

In light of two phase III randomized trials showing duloxetine (S1202) and acupuncture (S1200) both improve AIMSS, which would you try first? Wou...

Would the exact Oncotype score guide your decision (ie closer 25-30 v. >30-35)? NCCN recommends Oncotype only for tumor size < 5mm but this case...

If Oncotype is high risk, what regimen of adjuvant chemotherapy would you recommend?

Would you use a regimen with lower incidence of neurotoxicity such as CMF or a taxane-based regimen with a low threshold to dose-reduce?

Would you consider using ckd inhibitors in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Herceptin? NCCN ...

How do you approach treating ER/PR positive/HER-2 positive metastatic breast cancer? Do you combine hormonal therapy / chemotherapy and HER-2 directed...

We often treat elderly women with lumpectomy and adjuvant hormonal therapy without radiation. I am concerned about how to proceed after the 5 year poi...

Many women are distressed when asked to discontinue hormone replacement therapy or use intravaginal estrogen suppositories.

Some patients request chemotherapy scheduling adjustments to avoid feeling ill on major holidays. Delaying chemotherapy by a few days isn't of particu...

Example case: Patient given neoadjuvant docetaxel + cyclophophamide achieves a partial response after 3 cycles of Taxotere + cyclophosphamide but is u...

Are results of BCIRG-006 trial applicable for patients with triple positive breast cancer or only for those with HER2+? 

Tamoxifen prophylaxis is FDA-approved, but would you extrapolate from adjuvant/metatastic data for hormone receptor positive breast cancer in post-men...

In the absence of data demonstrating a clinical benefit for one strategy versus the other, what do you do in practice?  

Should one consider use of PARP inhibitor in a patient with metastatic triple negative breast cancer and finding of a somatic PALB2 mutation on genomi...

Given the data noting predictive benefit of utilizing genomic testing in predicting later relapse of hormone receptor positive breast cancer.

Being that there is limited data on CNS penetration with either regimen, what would you prefer in a patient who already received whole brain RT?

The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.

Do you have a cutoff in terms of tumor size, number of LN, Oncotype score, etc that makes you choose lower vs higher intensity chemo?

There is limited data that suggests steroidal AI exemestane could be of some benefit after nonsteroidal AI failure (Lonning PE et al. J Clin Oncol 200...

I.e. either for treatment of high-risk disease or intolerance/contraindication to tamoxifen. Will you continue it for the full 5 year course?

Aside from local therapies (intrathecal, radiation), are there therapies that are known to have better CNS penetration?

Assume good compliance with oral therapy, equivalent access to either agent, no contraindictions to either therapy, and absence of any visceral crisis...

Do you reserve this approach for only women with triple negative breast cancer or all-comers?

For example, does a higher recurrence score influence your choice of TC versus AC-T?  Or your choice to add ovarian suppression to a premenopausa...

What would you choose if there is no response to neoadjuvant AC-T? Taxol, THP, TCHP?

Do you prefer neoadjuvant chemotherapy or proceeding directly to surgery, followed by adjuvant therapy?  Which chemotherapy regimen do you recomm...

Assuming cytotoxic chemotherapy is given, would you still then proceed with adjuvant endocrine therapy?  Would you switch agents or classes of en...

(For instance, TCX4 instead of AC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemotherap...

Do you prefer this approach based on the FALCON trial showing improved PFS with frontline fulvestrant?

Do you extrapolate the results of OPTIMIZE-2 and CALGB 70604 showing that an every 12 week dosing of zolendronic acid is noninferior to ever...

Is there a select patient population that you use it for? Is it also being used in cancers other than breast cancer?

There are many options to choose from, including large gene panels with up to 80 genes at the same cost as BRCA 1/2 testing, while others offer j...

Is there a role for routine use of additional or alternative imaging modalities for these patients, such as tomosynthesis, MRI, or ultrasound?  I...

Some medical oncologists tend to hold anticoagulation in patients who develop brain metastases for fear of causing intracranial hemorrhage.  Is t...

Are there differences between palbociclib and ribociclib?  What would make you choose one over the other?

Is there any role for aromatase inhibitors?  What duration of therapy do you recommend?

For example, if a post-menopausal patient is treated in the first line setting with docetaxel, herceptin, and perjeta, would you add an aromatase...

At what point do you send these test, and in what instances do the results influence your treatment recommendations?

If so, how do you counsel patients who are node positive with low or intermediate risk scores? How do you interpret the existing data? NCCN and ASCO g...

In a patient who underwent lumpectomy for presumed DCIS and was found to have a focus of invasive triple negative disease, would you offer chemotherap...

Is a monthly schedule x 1 year, followed by q3 months, now the the standard of care, as per the recently published OPTIMIZE-2 trial? 

What tumor or patient characteristics lead you to consider the use of neoadjuvant hormonal therapy without chemotherapy?

This is rarely done, but recently came up in a tumor board discussion.  Which chemotherapy would you consider using, and when?

Do you consider placing an Ommaya for IT chemo with methotrexate or cytarabine? Knowing that leptomeningeal carcinomatosis carries such...

The CALOR study showed a benefit of adjuvant chemotherapy for local recurrence but the regimens given were "physicians choice".

How do you counsel them on risk in the curative setting?  Do you approach treatment in the metastatic setting any different than patients with &g...

Does switching AIs help?  If so, is there a role for switching from a steroidal AI to a non-steroidal AI or vice versa?  Are there other adj...

Based on results from PALOMA1 and recently reported MONALEESA2, do you use a CDK4/6 inhibitor as initial therapy?  In what circumstances would yo...

The results of the 70 gene panel Mammaprint in combination with Adjuvant! Online were published in NEJM recently. How will you incorporate this data i...

Do you ever consider de-escalating or stopping therapy in this situation? What is your approach to this conversation?

The MA17R trial only included "postmenopausal women" so how do you make a decision for men and pre-menopausal women.

Do you use cytotoxic chemotherapy as first line or hormonally-targeted therapy such as letrozole + palbociclib?

Based on the CALOR trial (http://www.ncbi.nlm.nih.gov/pubmed/24439313), adjuvant chemotherapy should be considered, but what regimen is preferred?&nbs...

In a patient who recently completed NAC, TM/LND and PMRT for a hormone positive locally advanced breast cancer and is then found to have a contralater...

The recently published MA.17R trial showed a DFS benefit for extending AI therapy to 10 years in post-menopausal women.

A recent publication of the TEXT and SOFT trials http://www.ncbi.nlm.nih.gov/pubmed/27044936 showed an improvement in breast cancer-fre...

Are there any clinical or pathologic factors that lean you towards or away from giving trastuzumab?

Our Radiation Safety officer reports a higher radiation dose to the patient from the two scans vs the PET.


Papers discussed in this category


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10

Annals of oncology : official journal of the European Society for Medical Oncology, 2011-11

N Engl J Med, 2015 Jan 8

International journal of radiation oncology, biology, physics, 2013-03-15

International journal of radiation oncology, biology, physics, 2011-05-01

International journal of radiation oncology, biology, physics, 2011-11-01

Lancet Oncol., 2012-01-01

The New England journal of medicine, 2015-02-19

Lancet Oncol., 2012-04-01

N. Engl. J. Med.,

The New England journal of medicine, 2016-07-21

N. Engl. J. Med., 2015-01-29

Breast cancer research : BCR, 2009

Cancer cell, 2012-10-16

Cancer cell, 2016-03-14

Cancer discovery, 2016-07

Clinical breast cancer, 2010-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10

The Lancet. Oncology, 2014-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-20

The breast journal, 1999-01

Annals of surgical oncology, 2010-10

Annals of surgical oncology, 2014-10

The New England journal of medicine, 2016-08-25

Cancer, 2015-12-15

Blood, 2015-07-23

The Lancet. Oncology, 2010-01

The New England journal of medicine, 2004-12-30

Lancet, 2015-10-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

Lancet Oncol., 2011 Jun 05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-06-10

International journal of radiation oncology, biology, physics, 2006-02-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15

Journal of the National Cancer Institute, 2001-12-05

International journal of radiation oncology, biology, physics, 2000-09-01

The New England journal of medicine, 2015-03-05

Lancet, 2007-05-19

Nat. Med.,

Lancet (London, England), 2016-12-17

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-10

Clinical breast cancer, 2006-12

Lancet (London, England), 2014-03-22

The New England journal of medicine, 2011-06-23

Journal of the National Cancer Institute, 2005-09-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-01

Lancet (London, England), 2009-12-19

The Lancet. Oncology, 2014-06

The New England journal of medicine, 2012-11-08

J. Clin. Oncol.,

Breast Cancer Res. Treat., 2013-01-01

J Clin Oncol, 2008 Jan 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20

National Cancer Institute (US),

ESMO Open, 2016-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

The New England journal of medicine, 2012-01-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10

J. Clin. Oncol., 2019 Oct 16

N. Engl. J. Med., 2017-07-13

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015-04

Am J Case Rep, 2017-02-28

Lancet, 2017-09-09

Breast cancer research and treatment, 2014-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

Oncologist, 2007-09-01

Journal of the National Cancer Institute, 2006-12-20

Medicine and science in sports and exercise, 2010-07

J Clin Oncol, 2016 Feb 20

Curr Breast Cancer Rep, 2016-01-01

Crit Rev Food Sci Nutr, 2018 Apr 19

JAMA, 2018-02-20

JAMA Oncol,

The New England journal of medicine, 2016-11-17

N. Engl. J. Med., 2016-11-03

The Lancet. Oncology, 2016-04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-09-01

JAMA, 2013-10-09

JAMA, 2011-02-09

Lancet Oncol., 2013-04-01

Lancet Oncol., 2014-11-01

Breast, 2017-02-01

J. Clin. Oncol., 2015-01-20

J. Clin. Oncol., 2009 Nov 02

The New England journal of medicine, 2012-08-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

Breast cancer research and treatment, 2012-11

British journal of clinical pharmacology, 2016-06

The New England journal of medicine, 2014-07-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01

Fertility and sterility, 2016-03

Breast Cancer, 2017-09-01

Journal of the National Cancer Institute, 2010-07-07

J Natl Cancer Inst, 2006 Jul 5

J. Natl. Cancer Inst., 2010-07-07

J. Clin. Oncol., 2003-10-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01

Breast Cancer Res. Treat., 2014-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

Lancet Oncol., 2014-06-01

Lancet Oncol., 2013-01-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2014-06

Lancet (London, England), 2013-03-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-20

Journal of the National Cancer Institute, 2013-07-17

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

Breast Cancer Res. Treat., 2005-01-01

Breast, 2016-12-01

Zhonghua Zhong Liu Za Zhi, 2016-07-01

Breast, 2016-08-01

N. Engl. J. Med., 2017 Jun 04

The New England journal of medicine, 2005-10-20

Springerplus, 2016-01-01

Lancet, 2017-03-25

N. Engl. J. Med., 2006-02-23

Lancet Oncol., 2013-07-01

Lancet Oncol., 2016-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-10

J. Clin. Oncol., 2015 Feb 17

The Lancet. Oncology, 2015-01

JAMA oncology, 2016-11-01

N Engl J Med, 2011 Oct 6

Eur. J. Cancer, 2017 Dec 08

Cancer, 2010-11-15

The breast journal, 2017-11

Lancet (London, England), 2016-02-27

JAMA Oncol, 2016 Mar

Clin Oncol (R Coll Radiol), 2016-12-01

The New England journal of medicine, 2009-05-14

Ann. Oncol., 2009-02-01

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-10-01

J. Clin. Oncol., 2011 Nov 21

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-01

J. Natl. Cancer Inst.,

J. Natl. Cancer Inst.,

Journal of the National Cancer Institute, 2014-01

Lancet Oncol., 2013 Jul 29

Ann. Oncol., 2010 May 21

Breast Cancer Res. Treat., 2010 Jul 15

J. Clin. Oncol., 2012 Feb 27

Cancer investigation, 2011-11

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-12-01

Cancer Treat. Rev., 2011-10-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07

Ann. Oncol., 2013-12-01

Nat Rev Clin Oncol, 2016-08-01

Acta Oncol, 2011-04-01

J. Clin. Oncol., 2011-06-01

N. Engl. J. Med.,

The Lancet. Oncology, 2018-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

N. Engl. J. Med., 2019 Jun 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Cancer, 2018-04-15

Proc Natl Acad Sci U S A, 2015 Aug 3

Journal of the National Cancer Institute, 2018-01-01

Pediatrics, 2014-04

Vaccine, 2014 Dec 08

Ann. Oncol., 2018 Jan 19

Journal of global oncology, 2017-08

Breast cancer research and treatment, 2018-02

Cochrane Database Syst Rev, 2008 Apr 16

Eur. J. Cancer, 2013 May 22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01

Ann. Oncol.,

Clin. Cancer Res., 2018 Mar 26

Ann. Oncol.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Radiother Oncol, 2017 Sep 27

Breast Cancer, 2012 Apr 25

Annals of surgical oncology, 2018-10

Lancet Oncol., 2015 Sep 09

Lancet,

Cancer, 2004-10-15

The New England journal of medicine, 2018-07-12

The New England journal of medicine, 2018-07-12

The Lancet. Oncology, 2018-01

Lancet Oncol., 2016 Jun 23

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-02-10

BMJ, 2016 Sep 30

International journal of radiation oncology, biology, physics, 2014-03-01

Breast cancer research and treatment, 2013-11

Annals of surgery, 2016-02

Breast cancer research and treatment, 2013-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-01

The Lancet. Oncology, 2016-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

Clinical breast cancer, 2018-02

Breast,

Journal of the National Cancer Institute, 2017-02

The Lancet. Oncology, 2018-04

JAMA Oncol,

Eur. J. Obstet. Gynecol. Reprod. Biol.,

Br J Obstet Gynaecol,

Annals of surgical oncology, 2016-02

JAMA oncology, 2016-09-01

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013-04

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-02-01

The Lancet. Oncology, 2017-12

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

The Lancet. Oncology, 2012-07

Annu. Rev. Med., 2015 Aug 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-06-20

Cancer research, 2008-10-01

N. Engl. J. Med.,

J. Clin. Oncol.,

NPJ breast cancer, 2016

Cancer, 2006-09-15

Breast Cancer,

N. Engl. J. Med.,

Breast Cancer Res. Treat.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-20

NPJ breast cancer, 2016

NPJ Breast Cancer,

Breast cancer research and treatment, 2011-04

Breast (Edinburgh, Scotland), 2015-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-20

Lancet Oncol., 2018 Nov 06

Lancet (London, England), 2014-07-12

The Lancet. Oncology, 2019-01

Breast cancer research and treatment, 2017-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-07-20

Mol Oncol,

Semin Oncol, 2006 Apr

Lancet,

Eur. J. Cancer, 2017 Aug 04

The New England journal of medicine, 2010-06-03

Journal of the National Cancer Institute, 1997-11-19

Lancet,

Ann Surg Oncol, 2018 Jul 9

JAMA, 2017-09-12

The Lancet. Oncology, 2013-10

J Clin Oncol, 2015 Aug 20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-01-01

NPJ breast cancer, 2017

N Engl J Med, 2018 Oct 20

Lancet Oncol., 2013 Dec 19

Curr Probl Cancer, 2016 Mar - Aug

Annals of surgical oncology, 2009-06

Annals of surgical oncology, 2017-02

Breast Cancer Res. Treat., 2017 Sep 15

JAMA, 2011-11-02

J. Clin. Oncol., 2018 May 30

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-20

The Lancet. Oncology, 2017-06

Breast cancer research : BCR, 2016-06-28

J Natl Cancer Inst, 2018 Jun 1

Oncology reviews, 2017-03-03

J Clin Oncol, 2011 Jan 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01

The New England journal of medicine, 2019-02-14

Lancet Oncol., 2017 Oct 12

The Lancet. Oncology, 2016-03

JAMA Oncol,

Liver Int., 2011 Aug 31

Lancet Oncol., 2017 Feb 24

Eur. J. Cancer, 2017 May 03

JAMA Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-10

JAMA, 2013-10-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04

Int. J. Radiat. Oncol. Biol. Phys.,

Breast cancer research and treatment, 2019-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-04-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-09-01

Breast Cancer Res Treat, 2009 Jun

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019-02

Lancet (London, England), 2016-02-27

Journal of the National Cancer Institute, 2001-11-07

Breast (Edinburgh, Scotland), 2019-04

Journal of clinical pathology, 2017-03

NPJ breast cancer, 2017

PLoS ONE, 2016 Oct 14

Sci Eng Ethics, 2017 Sep 15

Lancet, 2015 Mar 02

J. Clin. Oncol., 2018 Dec 06

Journal of the National Comprehensive Cancer Network : JNCCN, 2017-04

Breast cancer research and treatment, 2018-06

Trials, 2013 Aug 19

Ann. Oncol., 2012 Jun 06

Cancer,

Clin Transl Oncol, 2018 Mar 28

ISRN Surg, 2013 Mar 20

Ann. Surg.,

Journal of Cancer, 2017

Onco Targets Ther, 2018

Cancer cell, 2018-09-10

Cancer Discov, 2017 Mar

Mol Oncol, 2017 Nov 17

Nat Commun, 2016 May 13

JAMA oncology, 2016-10-01

The New England journal of medicine, 2019-06-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-01

N. Engl. J. Med.,

Breast Cancer Res Treat, 2019 Feb

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-12-01

J. Clin. Oncol., 2011 Jan 10

The New England journal of medicine, 2012-02-09

Cancer control : journal of the Moffitt Cancer Center, 2009-01

JAMA, 2015-07-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-11-10

Cochrane Database Syst Rev, 2013 Apr 30

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-15

J. Natl. Cancer Inst.,

Breast Cancer Res. Treat., 2019 May 31

PLoS ONE, 2018 May 16

Cancer discovery, 2012-11

Breast cancer research : BCR, 2016-12-13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01-10

Cochrane Database Syst Rev, 2019 Feb 18

JAMA oncology, 2019-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

Lancet Oncol., 2015-03-01

Ann. Surg. Oncol., 2013 Nov 23

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-02-01

The Lancet. Oncology, 2017-10

J. Clin. Oncol., 2019 Aug 28

JAMA oncology, 2017-11-01

Oncotarget,

Breast, 2013 Dec 22

Breast, 2015 Oct 09

NPJ Breast Cancer, 2016 Nov 16

Annals of surgery, 2019-03

Lancet (London, England), 2012-02-04

Annals of oncology : official journal of the European Society for Medical Oncology, 2018-08-01

Breast cancer research and treatment, 2008-01

Cancer, 1998-02-15

Cancer, 2010-04-15

Ann. Oncol., 2010 Jan 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-20

Curr Treat Options Oncol, 2019 Mar 14

Asian J Surg, 2019 Oct 26

SA J Radiol, 2018 Oct 29

Breast cancer research and treatment, 2016-04

J. Clin. Oncol., 2005 Feb 14

N. Engl. J. Med.,

Breast cancer research and treatment, 2011-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-05-01

N Engl J Med, 2005 Jun 2

N. Engl. J. Med.,

Cancer, 2016-04-15

JAMA, 2013-04-03

Ann. Oncol.,

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017-09

Springerplus, 2016 May 10

JAMA dermatology, 2018-06-01

The New England journal of medicine, 2016-07-07

J Clin Oncol. , 2019 Sep 1

Breast cancer research and treatment, 2017-08

Ann. Oncol.,

N. Engl. J. Med., 2019 Dec 11

The American journal of surgical pathology, 2017-11

Breast Cancer, 2016 Feb 13

Oncologist, 2020 Jul 03

The Lancet. Oncology, 2018-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-11-15

J. Clin. Oncol., 2010 May 10

BMJ (Clinical research ed.), 2010-03-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-01-01

Br. J. Cancer, 2013 Feb 05

JAMA Netw Open, 2020 Feb 05

Lancet Oncol., 2020 Feb 14

JAMA Oncol, 2019 Sep 30

J. Clin. Oncol., 2019 Jul 24

The Lancet. Oncology, 2010-10

Breast Cancer Res. Treat.,

Annals of surgical oncology, 2016-05

Oncology, 2020 Jan 09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01

The Lancet. Oncology, 2018-07

Anticancer Res.,

International journal of radiation oncology, biology, physics, 2005-07-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20

J. Clin. Oncol., 2019 Dec 05

J. Clin. Oncol., 2019 Oct 16

Journal of the National Cancer Institute, 1998-09-16

Lancet (London, England), 2002-09-14

Journal of the National Cancer Institute, 2007-05-02

Lancet,

Breast Cancer Res. Treat., 2006 May 11

The New England journal of medicine, 2018-08-23

Lancet Oncol., 2020 Mar 12

The Lancet. Oncology, 2017-08

Lancet Oncol., 2009 Nov 10

Breast cancer research and treatment, 2014-11